Abstract
The alpha emitter Radium-223 ((22)3Ra-Cl2) is a bone-seeking radionuclide studied as a new treatment for patients with bone metastases from hormone refractory prostate cancer. More than 1,000 patients have been included in clinical phase I-III tests showing significant reduction in alkaline phosphatase- and PSA level and prolonged survival. Adverse events are usually mild to moderate and comprise gastrointestinal and myelotoxic symp-toms. Intravenously administered (22)3Ra-Cl2 (half-life 11.4 days) will likely be given every four weeks for six treatments to out-patients.
| Original language | English |
|---|---|
| Journal | Ugeskrift for læger [online] |
| Volume | 176 |
| Issue number | 30 |
| Pages (from-to) | 1399-1402 |
| ISSN | 1603-6824 |
| Publication status | Published - 21 Jul 2014 |